MedTrace Logo

A Study of Rovalpituzumab Tesirine to Study Cardiac Ventricular Repolarization in Subjects With Small Cell Lung Cancer

NCT02874664 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 46

Last updated 2018-09-24

No results posted yet for this study

Summary

Study to evaluate the effect of rovalpituzumab tesirine on cardiac ventricular repolarization in subjects with small cell lung cancer (SCLC).

Conditions

  • Small Cell Lung Carcinoma

Interventions

DRUG

Rovalpituzumab Tesirine

Rovalpituzumab tesirine is a DLL3 targeted antibody drug conjugate (ADC)

Sponsors & Collaborators

  • Stemcentrx

    lead INDUSTRY

Principal Investigators

  • Daniel Da Costa, PharmD · AbbVie

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-09-30
Primary Completion
2018-09-12
Completion
2018-09-12

Countries

  • United States
  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02874664 on ClinicalTrials.gov